SCHEMBL24257761

SCHEMBL24257761

COc1c(C#N)ncc(Cc2ccccc2)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
LMNA P02545 4/20 0.37
GAA P10253 4/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
HPGD P15428 1/20 0.37
ALDH1A1 P00352 4/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
MAPT P10636 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAP2K1 Q02750 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
LTA4H P09960 1/20 0.37
HSP90AA1 P07900 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257703 0.74 ALDH1A1 (0.37) L3MBTL1HPGDALDH1A1CYP2C9CYP2C19
SCHEMBL24257758 0.74 POLB (0.41) LMNAGAAL3MBTL1ALDH1A1CYP2C19
SCHEMBL24257762 0.74 CNR2 (0.43) CNR2GPR55LMNAGAAALDH1A1
SCHEMBL26260178 0.73 AGXT (0.39) HPGDALDH1A1KDM4E
SCHEMBL26260120 0.72 MAOB (0.44) LMNAGAAL3MBTL1HPGDALDH1A1
SCHEMBL24257809 0.71 MAPK1 (0.49) LMNAL3MBTL1HPGDALDH1A1CYP2C9
SCHEMBL30452378 0.70 EGFR (0.32) HPGD
SCHEMBL24257705 0.70 EGFR (0.32) HPGD
SCHEMBL15281922 0.68 NAAA (0.44) LMNAGAAL3MBTL1HPGDALDH1A1
SCHEMBL8117734 0.67 CYP11B1 (0.49) LMNAGAAL3MBTL1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 CNR2 4211/4885GPR55 3258/4885LMNA 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.